6-K
File 001-11960
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 12 Jun 2024
- Reporting date
- 12 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
ASTRAZENECA PLC reports
- Company location
- Cambridge
- Fiscal year end
- 31 December
Company
Names, identifiers, and filing context for this profile.
1 identity field
SEC filing record 1 source field available
ASTRAZENECA PLC has filed 2,049 SEC EDGAR filings since 13 Mar 1995
SEC filing history
Showing 276-300 of 1,000 matching filings.
Per page
25
Current page
12
6-K
File 001-11960
FORM 6-K
- Filing date
- 04 Jun 2024
- Reporting date
- 04 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
25-NSE
File 001-11960
25-NSE filing
- Filing date
- 04 Jun 2024
- Reporting date
- Not listed
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
BLOCK LISTING INTERIM REVIEW
- Filing date
- 03 Jun 2024
- Reporting date
- 03 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
TOTAL VOTING RIGHTS
- Filing date
- 03 Jun 2024
- Reporting date
- 03 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
TAGRISSO PLUS CHEMO RECOMMENDED FOR APPROVAL IN EU
- Filing date
- 03 Jun 2024
- Reporting date
- 03 Jun 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
DATO-DXD IMPROVED OS IN NONSQUAMOUS LUNG CANCER
- Filing date
- 28 May 2024
- Reporting date
- 28 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
ASTRAZENECA TO DELIVER $80BN REVENUE BY 2030
- Filing date
- 21 May 2024
- Reporting date
- 21 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
ASTRAZENECA TO MANUFACTURE ADCS IN SINGAPORE
- Filing date
- 20 May 2024
- Reporting date
- 20 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
SUPERNOVA TRIAL MET COVID-19 PREVENTION ENDPOINT
- Filing date
- 16 May 2024
- Reporting date
- 16 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 15 May 2024
- Reporting date
- 15 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
ASTRAZENECA COMPLETES CELLECTIS EQUITY INVESTMENT
- Filing date
- 07 May 2024
- Reporting date
- 07 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
CALQUENCE COMBINATION IMPROVED PFS IN 1L MCL
- Filing date
- 02 May 2024
- Reporting date
- 02 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
TOTAL VOTING RIGHTS
- Filing date
- 01 May 2024
- Reporting date
- 01 May 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
TRUQAP RECOMMENDED FOR EU BREAST CANCER APPROVAL
- Filing date
- 29 Apr 2024
- Reporting date
- 29 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
ENHERTU IMPROVED PFS IN HER2-LOW AND ULTRALOW
- Filing date
- 29 Apr 2024
- Reporting date
- 29 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
1ST QUARTER RESULTS
- Filing date
- 25 Apr 2024
- Reporting date
- 25 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
RESULT OF AGM
- Filing date
- 11 Apr 2024
- Reporting date
- 11 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
ASTRAZENECA INCREASES 2024 DIVIDEND BY 7%
- Filing date
- 11 Apr 2024
- Reporting date
- 11 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
ENHERTU APPROVED IN US FOR HER2+ SOLID TUMOURS
- Filing date
- 08 Apr 2024
- Reporting date
- 08 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC
- Filing date
- 05 Apr 2024
- Reporting date
- 05 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
TOTAL VOTING RIGHTS
- Filing date
- 02 Apr 2024
- Reporting date
- 02 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
VOYDEYA APPROVED IN US
- Filing date
- 02 Apr 2024
- Reporting date
- 02 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
FDA ACCEPTS DATO-DXD BLA FOR BREAST CANCER
- Filing date
- 02 Apr 2024
- Reporting date
- 02 Apr 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-11960
ULTOMIRIS APPROVED IN THE US FOR NMOSD
- Filing date
- 25 Mar 2024
- Reporting date
- 25 Mar 2024
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing